Literature DB >> 1162080

Vasospastic diseases: a review.

J D Coffman, W T Davies.   

Abstract

Entities:  

Mesh:

Year:  1975        PMID: 1162080     DOI: 10.1016/0033-0620(75)90002-x

Source DB:  PubMed          Journal:  Prog Cardiovasc Dis        ISSN: 0033-0620            Impact factor:   8.194


× No keyword cloud information.
  10 in total

Review 1.  Use of nifedipine in hypertension and Raynaud's phenomenon.

Authors:  W Kiowski; P Erne; F R Bühler
Journal:  Cardiovasc Drugs Ther       Date:  1990-08       Impact factor: 3.727

Review 2.  Calcium antagonists in cerebral/peripheral vascular disorders. Current status.

Authors:  K J Tietze; M L Schwartz; P H Vlasses
Journal:  Drugs       Date:  1987-06       Impact factor: 9.546

Review 3.  Influence of vasospasm on visual function.

Authors:  P Gasser; J Flammer
Journal:  Doc Ophthalmol       Date:  1987-05       Impact factor: 2.379

4.  Effect of indoramin on finger blood flow in vasospastic patients.

Authors:  D L Clement
Journal:  Eur J Clin Pharmacol       Date:  1978-12-18       Impact factor: 2.953

5.  Cold-induced Raynaud's phenomenon ameliorated by intravenous administration of ketanserin: a double-blind cross-over study.

Authors:  H Baart de la Faille; H van Weelden; J D Banga; R G van Kesteren
Journal:  Arch Dermatol Res       Date:  1986       Impact factor: 3.017

6.  Treatment of Raynaud's phenomenon with the 5-HT2-receptor antagonist ketanserin.

Authors:  E Stranden; O K Roald; K Krohg
Journal:  Br Med J (Clin Res Ed)       Date:  1982-10-16

7.  Biofeedback treatment of Raynaud's disease and phenomenon.

Authors:  R R Freedman; S J Lynn; P Ianni; P A Hale
Journal:  Biofeedback Self Regul       Date:  1981-09

8.  Treatment of vasospastic disease with prostaglandin E1.

Authors:  P C Clifford; M F Martin; E J Sheddon; J D Kirby; R N Baird; P A Dieppe
Journal:  Br Med J       Date:  1980-10-18

9.  Prazosin treatment of primary Raynaud's phenomenon.

Authors:  S L Nielsen; K Vitting; K Rasmussen
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

10.  Reserpine treatment of Raynaud's disease.

Authors:  B A Nobin; S L Nielsen; B Eklov; N A Lassen
Journal:  Ann Surg       Date:  1978-01       Impact factor: 12.969

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.